Evidence-based writing on longevity, healthspan, and the science of ageing well.
Standard cholesterol tests are useful, but they do not always show the full picture. ApoB can provide a clearer measure of the number of atherogenic particles driving cardiovascular risk.
Biological age tests are increasingly popular, but their clinical value is often overstated. They may provide interesting signals, but they should not be confused with a diagnosis or a complete measure of health.
Blood pressure is not only a heart issue. Midlife hypertension can affect the brain's small vessels, increasing the long-term risk of cognitive decline, stroke and loss of independence.
GLP-1 medications are best known for weight loss, but their relevance to healthspan is broader. Their value depends on careful patient selection, monitoring and long-term clinical context.
Rapamycin is one of the most important drugs in ageing biology, with strong animal data and growing human interest. The key question is whether its effects on mTOR can translate into meaningful healthspan benefits in people.
Not every workout needs to be hard. Zone 2 training builds aerobic capacity, improves metabolic flexibility and supports long-term health in a way that high-intensity exercise alone cannot.
Eight hours in bed is not the same as eight hours of restorative sleep. Understanding sleep architecture changes how we think about optimising sleep for long-term health.
The supplement industry generates billions annually on promises of better health and longer life. Most products are not supported by robust evidence. A few are. Here is how to tell the difference.